BlackRock Inc. - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is and the CUSIP is 10806XAD4. A total of 35 filers reported holding BRIDGEBIO PHARMA INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$3,762,250
+44.2%
5,050,000
+18.8%
0.00%
Q2 2023$2,608,990
-3.7%
4,250,0000.0%0.00%
Q1 2023$2,708,738
+13.4%
4,250,000
-33.9%
0.00%
Q4 2022$2,389,329
-14.3%
6,425,0000.0%0.00%
Q3 2022$2,787,000
-7.5%
6,425,000
-12.9%
0.00%
Q2 2022$3,014,000
+48.8%
7,375,000
+68.6%
0.00%
Q1 2022$2,026,0004,375,0000.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2022
NameSharesValueWeighting ↓
INHERENT GROUP, LP 39,500,000$15,386,3964.59%
Athyrium Capital Management, LP 20,000,000$7,753,9003.26%
Diameter Capital Partners LP 43,287,000$16,786,9152.61%
Affinity Asset Advisors, LLC 10,000,000$3,895,2901.53%
DeepCurrents Investment Group LLC 39,355,000$14,590,7460.57%
BRAIDWELL LP 42,294,000$16,151,0210.54%
Context Capital Management, LLC 16,458$6,2850.46%
Aequim Alternative Investments LP 31,000,000$11,838,1250.32%
ARISTEIA CAPITAL, L.L.C. 40,816,000$15,586,6100.31%
ABSOLUTE INVESTMENT ADVISERS, LLC 5,000,000$1,875,0000.28%
View complete list of BRIDGEBIO PHARMA INC shareholders